Drugs / [225Ac]-FPI-2068
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06147037 | Jul 2024 → Dec 2026 expected | colorectal carcinoma, gastric cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma +2 | AstraZeneca | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [225Ac]-FPI-2068 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06147037 ↗ |
| Modality | Other / unclassified | “\[225Ac\]-FPI-2068 is a radiopharmaceutical therapy” NCT06147037 ↗ |
| Route | Intravenous | “dosed through IV administration” NCT06147037 ↗ |